



Contact: Jon Hawkinson
Location: Menlo Park, CA
Email: jhawkinson@omneuron.com
Tel: 650-585-5313
Website: <http://www.omneuron.com>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Profile

Industry Sector: Medical Devices

Company Overview: Omneuron is actively engaged in defining the clinical utility of real-time functional magnetic resonance imaging (rtfMRI). rtfMRI technology provides information on the level of activity in brain regions non-invasively. One implementation of this technology is to train patients to control the activation of brain regions involved in disease states. Current therapeutic applications include chronic pain and addiction.

Target Market(s): Physicians treating major diseases of the nervous system, chronic pain

Management

Leadership:

Christopher deCharms, CEO
 Jon Hawkinson, VP R&D

Key Value Drivers

Technology*: Omneuron is optimizing software and methods for training patients to control their own brain activation to ameliorate disease symptoms. Omneuron's software product, NeuroDirector®, allows brain activation to be measured in real time and delivered to patients inside an MRI scanner. Omneuron has also developed strategies employed by patients to improve the efficiency by which they learn to control brain activation. NeuroDirector® is compatible with commercial MRI scanners in wide use.

Competitive Advantage: Omneuron has developed the only rtfMRI product combining the power of real time analysis with the use of cognitive strategies to facilitate the training of patients to control the level of activation of regions of their own brains. This therapeutic approach is safe, non-invasive, does not rely on the administration of any drug or contrast agent, and has few or no side effects.

Plan & Strategy: Obtain strong efficacy data in clinical studies, then identify a strategic partner to complete clinical development and launch product.

*Technology funded by NIDA and NINDS and being commercialized under the NIH-CAP

Product Pipeline

